Interventional device developer Boston Scientific's proposed acquisition of Indianapolis-based Guidant took another step forward this week. The Natick, MA, company said it had signed an agreement containing consent orders from the U.S. Federal Trade Commission (FTC) that would resolve the agency's antitrust concerns over the deal.
The agreement is still subject to final review and approval by the FTC's commissioners, but Boston Scientific said the FTC signing resolves all outstanding antitrust issues with the FTC staff relating to the transaction. The company has also made commitments to European Commission (EC) regulatory authorities to assuage their antitrust concerns, and the European authorities are expected to conclude their review no later than April 18.
Boston Scientific said it expects the Guidant deal to close in the middle of April, after it receives FTC and EC regulatory approvals.
By AuntMinnie.com staff writers
April 6, 2006
Related Reading
Boston Scientific, Guidant deal gets shareholder nod, April 3, 2006
Guidant suspends Xience V supply, March 29, 2006
Guidant expands California facilities, March 17, 2006
Guidant launches new stent, March 10, 2006
Boston Scientific notifies EC of Guidant takeover, February 24, 2006
Copyright © 2006 AuntMinnie.com
